FDA approves Xenpozyme, first treatment for rare acid sphingomyelinase deficiency
The FDA has approved Xenpozyme as the first treatment for patients with acid sphingomyelinase deficiency with symptoms unrelated to the central nervous system.Acid sphingomyelinase deficiency…